​

Akari Therapeutics Stock (NASDAQ:AKTX)

ForecastOwnershipFinancialsChart
Akari Therapeutics by TradingView

Previous Close

$1.07

52W Range

$0.85 - $4.40

50D Avg

$1.11

200D Avg

$2.15

Market Cap

$13.52M

Avg Vol (3M)

$26.92K

Beta

0.58

Div Yield

-

AKTX Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

GB

Employees

9

IPO Date

Jan 06, 2014

Website

AKTX Performance

AKTX Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-16.81M$-23.09M$-17.21M
Net Income$-10.01M$-6.97M$-17.61M
EBITDA$-16.80M$-28.52M$-17.02M
Basic EPS$-2.04$-2.23$-8.20
Diluted EPS$-2.04$-2.23$-8.20

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q4 17Mar 21, 18 | 8:30 AM

Peer Comparison

TickerCompany
PCSAProcessa Pharmaceuticals, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
CAPRCapricor Therapeutics, Inc.
PULMPulmatrix, Inc.
SLNOSoleno Therapeutics, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
SLRXSalarius Pharmaceuticals, Inc.